From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Consider Not Giving EMIS a Miss when Researching an Outfit Set to Benefit from the Boom in Medicine

By Malcolm Stacey | Thursday 10 February 2022

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Hello Share Swaddlers. Family doctors are in demand more than usual in the wake of covid. Many more are being trained than is usual as it’s suddenly become a fashionable career and to serve an ageing population we’ll soon have many more medics per person. They all need tools for the job. And more and more reliance is being laid by medical folk on computers. Which brings me to today’s choice of EMIS Group (EMIS).

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



H&T Group – now again a Buy

Time left: 06:42:27